Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com

StockNews.com downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note released on Monday.

MCRB has been the subject of a number of other research reports. Chardan Capital decreased their price target on Seres Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a report on Wednesday, May 8th. Oppenheimer reaffirmed a market perform rating on shares of Seres Therapeutics in a report on Friday, June 7th. Finally, Canaccord Genuity Group cut their price objective on shares of Seres Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a report on Friday, June 7th.

Seres Therapeutics Price Performance

Seres Therapeutics stock opened at $0.70 on Monday. The firm has a market capitalization of $106.29 million, a P/E ratio of -1.17 and a beta of 1.98. The firm has a fifty day moving average of $0.88 and a 200-day moving average of $0.97. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $5.29.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. On average, research analysts expect that Seres Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in shares of Seres Therapeutics by 668.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 33,135 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Seres Therapeutics in the first quarter valued at about $39,000. SG Americas Securities LLC acquired a new stake in Seres Therapeutics during the fourth quarter valued at approximately $73,000. Virtu Financial LLC bought a new position in Seres Therapeutics during the 1st quarter worth approximately $73,000. Finally, Graham Capital Management L.P. grew its position in shares of Seres Therapeutics by 731.3% in the 3rd quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock worth $492,000 after acquiring an additional 181,957 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.